Fig. 5
From: Selective SERCA2a activator as a candidate for chronic heart failure therapy
In vivo effects during i.v. infusion in STZ rats. Compound 8 or vehicle (saline) was i.v. infused at 0.2 mg/kg/min under urethane anesthesia, in rats 8 weeks after STZ treatment. Echocardiographic parameters (see also Additional file 1: Figure S3) were measured under basal condition, at 15 and 30 min during drug infusion. Data are mean ± SEM. Saline group N = 8, compound 8 group N = 11; *p < 0.05 vs saline group for the interaction factor in RM two-way ANOVA. E, A: early and late mitral inflow velocities; DT E wave deceleration time; e’ early diastolic mitral annulus velocity; LVEDD LV end diastolic diameter; SV stroke volume; CO cardiac output; HR heart rate: s’ peak systolic tissue velocity